| abstract |
Provided herein are methods for the treatment of Alport syndrome using modified oligonucleotides that target miR-21. In certain embodiments, a modified oligonucleotide targeting miR-21 improves renal function and / or reduces fibrosis in a subject with Alport syndrome. In certain embodiments, administration of a modified oligonucleotide targeting miR-21 delays the onset of end-stage renal disease in a subject with Alport syndrome. In certain embodiments, modified oligonucleotides that target miR-21 delay the need for dialysis or kidney transplantation of subjects with Alport syndrome. [Selection figure] None |